UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study

Arthritis & rheumatology (Hoboken, N.J.), 2017-05, Vol.69 (5), p.1016-1027

2017

Volltextzugriff (PDF)

Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers

Clinical cancer research, 2007-10, Vol.13 (20), p.6187-6194

2007

Volltextzugriff (PDF)

Phase I Pharmacokinetic and Biologic Correlative Study of Mapatumumab, a Fully Human Monoclonal Antibody With Agonist Activity to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor-1

Journal of clinical oncology, 2007-04, Vol.25 (11), p.1390-1395

2007

Volltextzugriff (PDF)

A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies

Clinical cancer research, 2008-06, Vol.14 (11), p.3450-3455

2008

Volltextzugriff (PDF)

Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study

Journal of clinical oncology, 2009-09, Vol.27 (26), p.4413-4421

2009

Volltextzugriff (PDF)

Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

Clinical cancer research, 2009-09, Vol.15 (17), p.5584-5590

2009

Volltextzugriff (PDF)

Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study

Lupus science & medicine, 2018-11, Vol.5 (1), p.e000288-e000288

2018

Volltextzugriff (PDF)

Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: The ASSENT-1 trial

The American heart journal, 1999-05, Vol.137 (5), p.786-791

1999

Volltextzugriff (PDF)

10 Years of belimumab experience: What have we learnt?

Lupus, 2021-10, Vol.30 (11), p.1705-1721

2021

Volltextzugriff (PDF)

Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis

Journal of clinical psychopharmacology, 2020-05, Vol.40 (3), p.231-239

2020

Volltextzugriff (PDF)

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus

Arthritis care & research (2010), 2022-11, Vol.74 (11), p.1822-1828

2022

Volltextzugriff (PDF)

Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study

Annals of the rheumatic diseases, 2024-08, p.ard-2024-225686

2024

Volltextzugriff (PDF)

Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus

Rheumatology (Oxford, England), 2024-09, Vol.63 (9), p.2387-2398

2024

Volltextzugriff (PDF)

Laying strong foundations

Reproductive biomedicine online, 2011, Vol.23, p.26-27

Fox, Norma Lynn

2011

Volltextzugriff (PDF)

Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer

Clinical lung cancer, 2014-05, Vol.15 (3), p.188-196.e2

2014

Volltextzugriff (PDF)

Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus

International journal of clinical pharmacology and therapeutics, 2016-11, Vol.54 (11), p.914-922

2016

Volltextzugriff (PDF)

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-1 and receptor-2 agonists for cancer therapy

Expert opinion on biological therapy, 2010-01, Vol.10 (1), p.1-18

2010

Volltextzugriff (PDF)

Quality of Life After Coronary Artery Bypass Graft

Chest, 2004-08, Vol.126 (2), p.487-495

2004

Volltextzugriff (PDF)

Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects

Clinical pharmacology in drug development, 2016-05, Vol.5 (3), p.208-215

2016

Volltextzugriff (PDF)

Final analysis: Randomized, blinded, placebo-controlled phase II trial of sorafenib with and without mapatumumab in patients with advanced hepatocellular carcinoma (HCC)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.4029-4029

2014

Volltextzugriff (PDF)

TNK-tissue plasminogen activator in acute myocardial infarction : Results of the thrombolysis in myocardial infarction (TIMI) 10A dose-ranging trial

Circulation (New York, N.Y.), 1997-01, Vol.95 (2), p.351-356

1997

Volltextzugriff (PDF)

Correlation of CT findings with clinical evaluations in 261 patients with symptomatic bronchiectasis

American journal of roentgenology (1976), 1999-07, Vol.173 (1), p.53-58

1999

Volltextzugriff (PDF)

Quality of life after coronary artery bypass graft: Results from the POST CABG Trial

Chest, 2004-08, Vol.126 (2), p.487-495

2004

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of Tenecteplase: Results from a Phase II Study in Patients with Acute Myocardial Infarction

Journal of clinical pharmacology, 2000-05, Vol.40 (5), p.508-515

2000

Volltextzugriff (PDF)

Prenatal Exposure to Tobacco: II Effects on Cognitive Functioning at Age Three

International journal of epidemiology, 1990-03, Vol.19 (1), p.72-77

1990

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(40)

Sprache

Englisch
(40)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(31)
Science & Technology
(31)
Humans
(27)
Female
(24)
Adult
(18)
Male
(18)
Biological And Medical Sciences
(17)
Medical Sciences
(17)
Middle Aged
(15)
Aged
(13)
Treatment Outcome
(11)
Pharmacology. Drug Treatments
(9)
Blood. Blood Coagulation. Reticuloendothelial System
(6)
Cardiac & Cardiovascular Systems
(6)
Cardiovascular System & Cardiology
(6)
Dose-Response Relationship, Drug
(6)
Neoplasms - Drug Therapy
(6)
Oncology
(6)
Patients
(6)
Rheumatology
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study

Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers

Phase I Pharmacokinetic and Biologic Correlative Study of Mapatumumab, a Fully Human Monoclonal Antibody With Agonist Activity to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor-1

A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies

Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study

Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study

Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: The ASSENT-1 trial

10 Years of belimumab experience: What have we learnt?

Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus

Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study

Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus

Laying strong foundations

Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer

Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-1 and receptor-2 agonists for cancer therapy

Quality of Life After Coronary Artery Bypass Graft

Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects

Final analysis: Randomized, blinded, placebo-controlled phase II trial of sorafenib with and without mapatumumab in patients with advanced hepatocellular carcinoma (HCC)

TNK-tissue plasminogen activator in acute myocardial infarction : Results of the thrombolysis in myocardial infarction (TIMI) 10A dose-ranging trial

Correlation of CT findings with clinical evaluations in 261 patients with symptomatic bronchiectasis

Quality of life after coronary artery bypass graft: Results from the POST CABG Trial

Pharmacokinetics and Pharmacodynamics of Tenecteplase: Results from a Phase II Study in Patients with Acute Myocardial Infarction

Prenatal Exposure to Tobacco: II Effects on Cognitive Functioning at Age Three

Suchergebnisse filtern